{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T02:04:56Z","timestamp":1775873096827,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s12325-024-02897-8","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:19:04Z","timestamp":1722363544000},"page":"3615-3632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current Challenges of Using Patient-Level Claims and Electronic Health Record Data for the Longitudinal Evaluation of Duchenne Muscular Dystrophy Outcomes"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6382-614X","authenticated-orcid":false,"given":"Katherine L.","family":"Gooch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Audhya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Ricchetti-Masterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelagh M.","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"issue":"3","key":"2897_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265879","volume":"17","author":"N Ferizovic","year":"2022","unstructured":"Ferizovic N, Summers J, de Z\u00e1rate IBO, et al. Prognostic indicators of disease progression in Duchenne muscular dystrophy: a literature review and evidence synthesis. PLoS ONE. 2022;17(3):e0265879.","journal-title":"PLoS ONE"},{"key":"2897_CR2","doi-asserted-by":"publisher","first-page":"1183101","DOI":"10.3389\/fphys.2023.1183101","volume":"14","author":"A Bez Batti Angulski","year":"2023","unstructured":"Bez Batti Angulski A, Hosny N, Cohen H, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023;14:1183101.","journal-title":"Front Physiol"},{"issue":"23","key":"2897_CR3","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology. 2021;97(23):e2304\u201314.","journal-title":"Neurology"},{"issue":"3","key":"2897_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"21","key":"2897_CR5","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1212\/WNL.0000000000002147","volume":"85","author":"L Peverelli","year":"2015","unstructured":"Peverelli L, Testolin S, Villa L, et al. Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy. Neurology. 2015;85(21):1886\u201393.","journal-title":"Neurology"},{"key":"2897_CR6","doi-asserted-by":"publisher","first-page":"1276144","DOI":"10.3389\/fped.2023.1276144","volume":"11","author":"E Mercuri","year":"2023","unstructured":"Mercuri E, Pane M, Cicala G, Brogna C, Ciafaloni E. Detecting early signs in Duchenne muscular dystrophy: comprehensive review and diagnostic implications. Front Pediatr. 2023;11:1276144.","journal-title":"Front Pediatr"},{"issue":"10","key":"2897_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108205","volume":"9","author":"M Pane","year":"2014","unstructured":"Pane M, Mazzone ES, Sivo S, et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS ONE. 2014;9(10):e108205.","journal-title":"PLoS ONE"},{"issue":"1","key":"2897_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2897_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10654-021-00819-4","volume":"37","author":"L Wahlgren","year":"2022","unstructured":"Wahlgren L, Kroksmark AK, Tulinius M, Sofou K. One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure. Eur J Epidemiol. 2022;37(2):147\u201356.","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"2897_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.nmd.2021.06.001","volume":"31","author":"C Campbell","year":"2021","unstructured":"Campbell C, McColl E, McDermott MP, Martens WB, Guglieri M, Griggs RC. Health related quality of life in young, steroid-na\u00efve boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2021;31(11):1161\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"10119","key":"2897_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451\u201361.","journal-title":"Lancet"},{"issue":"10","key":"2897_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/dmcn.13934","volume":"60","author":"E Landfeldt","year":"2018","unstructured":"Landfeldt E, Edstr\u00f6m J, Buccella F, Kirschner J, Lochm\u00fcller H. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol. 2018;60(10):987\u201396.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"2897_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/JND-230220","volume":"11","author":"E Landfeldt","year":"2024","unstructured":"Landfeldt E, Alem\u00e1n A, Abner S, et al. Predictors of loss of ambulation in Duchenne muscular dystrophy: a systematic review and meta-analysis. J Neuromuscul Dis. 2024;11(3):579\u2013612.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"2897_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mus.23808","volume":"48","author":"EK Henricson","year":"2013","unstructured":"Henricson EK, Abresch RT, Cnaan A, et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve. 2013;48(1):55\u201367.","journal-title":"Muscle Nerve"},{"key":"2897_CR15","unstructured":"KPMG. Pathway to success in outcome-based contracting: navigating payer needs. 2020. https:\/\/assets.kpmg.com\/content\/dam\/kpmg\/ch\/pdf\/pathway-to-success-in-outcome-based-contracting.pdf. Accessed 30 May 2024."},{"issue":"9","key":"2897_CR16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2012.12.008","volume":"61","author":"G Schram","year":"2013","unstructured":"Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol. 2013;61(9):948\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2897_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347\u201361.","journal-title":"Lancet Neurol"},{"key":"2897_CR18","unstructured":"US Food and Drug Administration. EXONDYS 51 (eteplirsen) injection, for intravenous use. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206488s027s028s029lbl.pdf. Accessed 30 May 2024."},{"key":"2897_CR19","unstructured":"US Food and Drug Administration. VYONDYS 53 (golodirsen). 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211970s002lbl.pdf. Accessed 30 May 2024."},{"key":"2897_CR20","unstructured":"US Food and Drug Administration. Package insert - ELEVIDYS. 2023. https:\/\/www.fda.gov\/media\/169679\/download?attachment. Accessed 28 May 2024."},{"issue":"15","key":"2897_CR21","doi-asserted-by":"publisher","first-page":"e1540","DOI":"10.1212\/WNL.0000000000201626","volume":"100","author":"F Muntoni","year":"2023","unstructured":"Muntoni F, Signorovitch J, Sajeev G, et al. DMD genotypes and motor function in Duchenne muscular dystrophy: a multi-institution meta-analysis with implications for clinical trials. Neurology. 2023;100(15):e1540\u201354.","journal-title":"Neurology"},{"issue":"9","key":"2897_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221097","volume":"14","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Domingos J, Manzur AY, et al. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. PLoS ONE. 2019;14(9):e0221097.","journal-title":"PLoS ONE"},{"key":"2897_CR23","doi-asserted-by":"crossref","unstructured":"Szabo SM, Klimchak AC, Qian C, Iannaccone S, Popoff E, Gooch KL. Characterizing the occurrence of key clinical milestones in Duchenne muscular dystrophy in the United States using real-world data. J Neuromuscul Dis. 2022;9(6):689\u201399.","DOI":"10.3233\/JND-220816"},{"issue":"6","key":"2897_CR24","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","volume":"39","author":"J Iff","year":"2022","unstructured":"Iff J, Zhong Y, Gupta D, et al. Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records. Adv Ther. 2022;39(6):2906\u201319.","journal-title":"Adv Ther"},{"issue":"10","key":"2897_CR25","first-page":"1426","volume":"27","author":"AC Klimchak","year":"2021","unstructured":"Klimchak AC, Szabo SM, Qian C, Popoff E, Iannacccone S, Gooch K. Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage. J Manag Care Spec Pharm. 2021;27(10):1426\u201337.","journal-title":"J Manag Care Spec Pharm"},{"key":"2897_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/9781119413431","volume-title":"Pharmacoepidemiology","author":"BLKS Strom","year":"2019","unstructured":"Strom BLKS, Hennessy S. Pharmacoepidemiology. 6th ed. Wiley; 2019.","edition":"6"},{"issue":"2","key":"2897_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ana.25951","volume":"89","author":"Y de Feraudy","year":"2021","unstructured":"de Feraudy Y, Ben Yaou R, Wahbi K, et al. Very low residual dystrophin quantity is associated with milder dystrophinopathy. Ann Neurol. 2021;89(2):280\u201392.","journal-title":"Ann Neurol"},{"issue":"9","key":"2897_CR28","first-page":"1033","volume":"29","author":"R Schrader","year":"2023","unstructured":"Schrader R, Posner N, Dorling P, et al. Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims. J Manag Care Spec Pharm. 2023;29(9):1033\u201344.","journal-title":"J Manag Care Spec Pharm"},{"key":"2897_CR29","unstructured":"Clarivate. Real world data: gain patient insights today for a healthier tomorrow. https:\/\/clarivate.com\/products\/real-world-data\/. Accessed 30 May 2024."},{"key":"2897_CR30","unstructured":"US Food and Drug Administration. AMONDYS 45 (casimersen) 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213026lbl.pdf. Accessed 30 May 2024."},{"issue":"3","key":"2897_CR31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/mus.27463","volume":"65","author":"SM Szabo","year":"2022","unstructured":"Szabo SM, Gooch KL, Mickle AT, Salhany RM, Connolly AM. The impact of genotype on outcomes in individuals with Duchenne muscular dystrophy: a systematic review. Muscle Nerve. 2022;65(3):266\u201377.","journal-title":"Muscle Nerve"},{"issue":"S2","key":"2897_CR32","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.2105\/AJPH.2021.306418","volume":"111","author":"JC Young","year":"2021","unstructured":"Young JC, Pack C, Gibson TB, et al. Machine learning can unlock insights into mortality. Am J Public Health. 2021;111(S2):S65\u20138.","journal-title":"Am J Public Health"},{"issue":"11","key":"2897_CR33","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s40264-019-00827-0","volume":"42","author":"JM Reps","year":"2019","unstructured":"Reps JM, Rijnbeek PR, Ryan PB. Identifying the DEAD: development and validation of a patient-level model to predict death status in population-level claims data. Drug Saf. 2019;42(11):1377\u201386.","journal-title":"Drug Saf"},{"issue":"6","key":"2897_CR34","first-page":"633","volume":"23","author":"S Thayer","year":"2017","unstructured":"Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Pharm. 2017;23(6):633\u201341.","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"2897_CR35","doi-asserted-by":"publisher","DOI":"10.2196\/publichealth.6720","volume":"3","author":"MG Smith","year":"2017","unstructured":"Smith MG, Royer J, Mann JR, McDermott S. Using administrative data to ascertain true cases of muscular dystrophy: rare disease surveillance. JMIR Public Health Surveill. 2017;3(1):e2.","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"2897_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/0883073818801704","volume":"34","author":"KM Sahay","year":"2019","unstructured":"Sahay KM, Smith T, Conway KM, et al. A review of MD STAR net\u2019s research contributions to pediatric-onset dystrophinopathy in the United States; 2002\u20132017. J Child Neurol. 2019;34(1):44\u201353.","journal-title":"J Child Neurol"},{"key":"2897_CR37","doi-asserted-by":"crossref","unstructured":"Adorisio R, Mencarelli E, Cantarutti N, et al. Duchenne dilated cardiomyopathy: cardiac management from prevention to advanced cardiovascular therapies. J Clin Med. 2020;9(10):3186.","DOI":"10.3390\/jcm9103186"},{"issue":"4","key":"2897_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","volume":"32","author":"F Muntoni","year":"2022","unstructured":"Muntoni F, Signorovitch J, Sajeev G, et al. Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. Neuromuscul Disord. 2022;32(4):271\u201383.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2897_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, et al. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 2016;87(4):401\u20139.","journal-title":"Neurology"},{"issue":"3","key":"2897_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JND-210746","volume":"9","author":"KS Nair","year":"2022","unstructured":"Nair KS, Lott DJ, Forbes SC, et al. Step activity monitoring in boys with Duchenne muscular dystrophy and its correlation with magnetic resonance measures and functional performance. J Neuromuscul Dis. 2022;9(3):423\u201336.","journal-title":"J Neuromuscul Dis"},{"key":"2897_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.594446","volume":"11","author":"S Michelsen","year":"2020","unstructured":"Michelsen S, Nachi S, Van Dyck W, Simoens S, Huys I. Barriers and opportunities for implementation of outcome-based spread payments for high-cost, one-shot curative therapies. Front Pharmacol. 2020;11:594446.","journal-title":"Front Pharmacol"},{"issue":"4","key":"2897_CR42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/rme-2020-0169","volume":"16","author":"J J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen J, Kefalas P. The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med. 2021;16(4):405\u201322.","journal-title":"Regen Med"},{"key":"2897_CR43","unstructured":"Pfizer. Pfizer Pledge Program: a warranty program for patients starting XALKORI. 2022. https:\/\/www.xalkori.com\/financial-assistance. Accessed 7 May 2024."},{"key":"2897_CR44","unstructured":"bluebird bio, Inc. bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO\u00ae, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions [press release]. 2022. https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-announces-us-commercial-infrastructure-enable. Accessed 30 May 2024."},{"issue":"1","key":"2897_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40273-021-01070-1","volume":"40","author":"N Bohm","year":"2022","unstructured":"Bohm N, Bermingham S, Grimsey Jones F, Gon\u00e7alves-Bradley DC, Diamantopoulos A, Burton JR, et al. The challenges of outcomes-based contract implementation for medicines in Europe. Pharmacoeconomics. 2022;40(1):13\u201329.","journal-title":"Pharmacoeconomics"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02897-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02897-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02897-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T22:09:06Z","timestamp":1724796546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02897-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02897-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katherine Gooch, Ivana Audhya, Kristen Ricchetti-Masterson are employees of Sarepta Therapeutics, Inc. and may have stock options. Shelagh M. Szabo is an employee of Broadstreet HEOR, which received funds from Sarepta related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"MarketScan and Clarivate data are de-identified and do not require institutional review board review. The authors obtained permission to access and use the data from the owners of the MarketScan and Clarivate databases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}